17/05/22

Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease

Inflamm Bowel Dis 2022 Mar 30;28(4):560-571. Sebastian Bruno Ulrich Jordi , Brian Matthew Lang , Bianca Auschra et al AbstractBackground:Inflammatory bowel disease (IBD) patients are at high risk for depression, and depression has been shown to affect disease course. We…
17/05/22

Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels

Inflamm Bowel Dis 2022 May 4;28(5):720-727. Xavier Roblin , Capucine Genin , Stéphane Nancey et al AbstractBackground:In cases of loss of response due to mechanistic failure under antitumor necrosis factor agents, it is recommended to switch to another class of…
17/05/22

Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions

Aliment Pharmacol Ther 2022 May;55(9):1139-1150. Salam P Bachour , Ravi S Shah , Ruishen Lyu , et al AbstractThere are conflicting data assessing the impact of isolated post-operative anastomotic inflammation on future disease progression. The aim of this study was…
17/05/22

Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease

Aliment Pharmacol Ther 2022 Jun;55(11):1389-1401. Viktoria Bergqvist , Johanna Holmgren , Daniel Klintman , Jan Marsal Background and AimsVedolizumab is a gut-selective treatment approved for Crohn’s disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of vedolizumab was approved.…
11/03/22

Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease

Giorgos Bamias, MD, PhD, Theresa T Pizarro, PhD, Fabio Cominelli, MD, PhD Author Notes Inflammatory Bowel Diseases, Volume 28, Issue 3, March 2022, Pages 337–349, https://doi.org/10.1093/ibd/izab251 Published: Abstract Intestinal fibrosis is a late-stage phenotype of inflammatory bowel disease (IBD), which…
11/03/22

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Stefanie Howaldt, MD, Eugeni Domènech, MD, PhD, Nicholas Martinez, MD, Carsten Schmidt, MD, Bernd Bokemeyer, MD on behalf of the AEGIS Trialists Inflammatory Bowel Diseases, Volume 28, Issue 3, March 2022, Pages 373–384, https://doi.org/10.1093/ibd/izab073 Abstract Background Iron-deficiency anemia is common…
11/03/22

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease

Ruben J Colman , Ye Xiong , Tomoyuki Mizuno , Jeffrey S Hyams, Joshua D Noe , Brendan Boyle, Geert R D'Haens, Johan van Limbergen, Kelly Chun, Jane Yang, Michael J Rosen, Lee A Denson, Alexander A Vinks, Phillip Minar…
11/03/22

Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero

Emma Flanagan , Ralley Prentice , Emily K Wright , Peter R Gibson , Alyson L Ross , Jakob Begun, Miles P Sparrow, Rimma Goldberg, Ourania Rosella, Megan Burns , Katerina V Kiburg , Sally J Bell Abstract Background: Ustekinumab…
11/02/22

Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor

Laurène Parrot,Catherine Dong,Franck Carbonnel,Antoine Meyer First published: 01 December 2021 https://doi.org/10.1111/apt.16714 Background Ustekinumab and vedolizumab are commonly used after anti-tumour necrosis factor (TNF) failure in patients with Crohn’s disease (CD). No randomised controlled trial has compared these drugs. AimsTo compare…
11/02/22

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Séverine Vermeire, Geert D’Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus, Jr, Siddharth Bhatia, Christian Agboton, Maria Rosario, Chunlin Chen, Wenwen Zhang, Krisztina Kisfalvi, William J Sandborn Journal of Crohn's and Colitis, Volume 16, Issue 1, January 2022,…
11/02/22

Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn’s Disease

Scott David Lee, Anand Singla, Jason Harper, Mitra Barahimi, Jeffrey Jacobs, Kendra J Kamp, Kindra Dawn Clark-Snustad Inflammatory Bowel Diseases, Volume 28, Issue 2, February 2022, Pages 309–313 Abstract BackgroundThe majority of patients with Crohn’s disease (CD) will not achieve…